Rapigen's Rapid Test Kits for Mosquito-Borne Diseases Recognized as Next-Generation World-Class Products

Rapigen, a leading South Korean in-vitro diagnostics company, announced that its rapid diagnostic kits for mosquito-borne diseases—specifically malaria, dengue fever, and Zika virus—have been designated as "Next-Generation World-Class Products" by the Ministry of Trade, Industry and Energy and the Korea Trade-Investment Promotion Agency (KOTRA).

This prestigious recognition is awarded to products that demonstrate strong global competitiveness and significant growth potential. To qualify, products must meet criteria such as receiving government support for development, obtaining new technology or product certifications within the past three years, or achieving an average annual export growth rate surpassing the national average over the same period.

Among the recognized products, Rapigen's malaria rapid diagnostic kit has garnered international acclaim. It has received Emergency Use Listing (ERPD) certification from the Global Fund and is currently undergoing the World Health Organization's Prequalification (PQ) process. In 2023, the WHO recommended its use, acknowledging its technological excellence.

Further solidifying its global standing, Rapigen was designated as a G-PASS (Government Performance ASSured) company by the Public Procurement Service in the first quarter of 2024. This designation highlights the company's technological prowess and reliability, identifying it as a promising enterprise for international procurement markets.

CEO Park Jae-gu expressed confidence in Rapigen's global competitiveness, stating, "With our second-generation malaria diagnostic kit's superior quality and production capacity, we aim to establish Rapigen's presence on the global stage."

For more information, please visit Rapigen's official website.